Lithuania yesterday opened a trade office in Taiwan, potentially escalating tensions with China that have been simmering since the EU member state drew a stiff rebuke from Beijing.
The trade office’s opening comes a year after the government in Taipei opened an office in Lithuania’s capital, Vilnius. China responded by downgrading diplomatic relations with the Baltic state over the office’s explicit use of the name Taiwan.
The new Lithuanian trade office carries the name Taipei, which might avoid a harsher reaction from Beijing.
Photo: Ann Wang, Reuters
“Today we can rejoice over the first achievements of Lithuanian cooperation with Taiwan,” Lithuanian Minister of the Economy and Innovation Ausrine Armonaite said in a statement. “I have no doubt that our work with this promising market will intensify further after the opening of the Lithuanian trade office in Taipei.”
The dispute between China and Lithuania, a Baltic nation of 2.8 million, has helped roil relations between the world’s most populous nation and the EU as a whole.
After Taiwan’s trade office opened, China withdrew its ambassador and faced accusations of halting the clearance of Lithuanian goods in its ports. The standoff prompted the EU to raise the issue of trade hurdles with the WTO.
Photo courtesy of the Ministry of Foreign Affairs
Lithuanian President Gitanas Nauseda last month said China’s punitive action and its backing of Russia’s invasion of Ukraine showed that Beijing is the EU’s “systemic rival.”
Meanwhile, British Minister of State for Trade Policy Greg Hands held talks with Taiwanese officials in Taipei to “future-proof” Britain’s economy in the coming decades, as British Prime Minister Rishi Sunak’s administration looks to take a tougher stance on China.
After exports to China effectively stalled, Lithuania compensated for its losses by increasing its sales to 10 other markets in the Indo-Pacific region by 60 percent in the first eight months of the year, the Lithuanian Ministry of Economy said.
Taiwan yesterday also announced its first 3.5 million euro (US$3.49 million) investment in Lithuania’s ultra-fast laser technology producer Litilit.
Two more investments in Lithuania are to be announced later this year or by early next year to bring the total to 10 million euros, officials in Taipei said.
The Litilit investment was the first made by Taiwan’s US$200 million Central and Eastern Europe Investment fund, set up after Lithuania allowed Taiwan to open a de facto embassy on its soil in November last year.
The fund focuses on Lithuania, Slovakia and the Czech Republic.
Taiwan, the world's biggest supplier of semiconductors, will invest more than 10 million euros towards chip production in Lithuania, the head of the Taiwanese representative office in Vilnius said yesterday.
The Industrial Technology and Research Institute (工業技術研究院) will cooperate with Lithuania's electronics manufacturer Teltonika to build semiconductor technology capabilities in the Baltic country, Representative to Lithuania Eric Huang (黃鈞耀) said.
Over two dozen Taiwanese scholarships for Lithuanians will be offered for technical training, he added.
"This is not a transaction (in exchange of Lithuania allowing opening of the office)," Huang said. "It is because Taiwan would like to work with Lithuania together to strengthen the resilience of our democratic supply chain in the face of coercion by autocracies."
Earlier this year, Taiwan launched a 200-million-euro equity investment fund and a 1-billion-euro loan facility for Lithuania and other central and eastern European countries.
The first equity investments totaling 10 million euros in Lithuanian would be completed by early next year, said Huang, adding that first loans amounting to 9 million euros should be dispersed by the end of this month.
Taiwan also granted import permits for Lithuanian diary, fish and egg products, and could allow imports of its beef by the end of the year.
Additional reporting by Reuters
UNCONVINCING: The US Congress questioned whether the company’s Chinese owners pose a national security risk and how the app might influence young users TikTok chief executive officer Shou Chew (周受資), confronted with an unforgiving, distrustful US Congress, tried to give answers in his testimony on Thursday that avoided offending either the US government or China. However, his evasiveness left Congress unsatisfied, with representatives hungrier than ever to punish TikTok for ties to its parent company ByteDance Ltd (字節跳動), based in Beijing. He did not bring his company any closer to a resolution. Politically, TikTok is in a tougher spot. Its executives had been discussing divesting from ByteDance to resolve US national security concerns, people familiar with the matter told Bloomberg. However, China this week said
The Investment Commission yesterday approved a Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) application to invest an additional US$3.5 billion in its Arizona subsidiary to manufactured advanced chips. The world’s largest contract chipmaker’s board of directors last month approved the funding project after TSMC started moving manufacturing equipment into the fab in December last year in preparation for the production of 4-nanometer chips next year. TSMC said it has also commenced the second phase of facility construction in Arizona. The second fab is to produce semiconductors using 3-nanometer technology in 2026. Altogether, TSMC plans to spend US$40 billion on the Arizona fabs, doubling its
Microsoft Corp has threatened to cut off access to its Internet search data, which it licenses to rival search engines, if they do not stop using it as the basis for their own artificial intelligence (AI) chat products, people familiar with the dispute have said. The software maker licenses the data in its Bing search index — a map of the Internet that can be quickly scanned in real time — to other companies that offer Web search, such as Apollo Global Management Inc’s Yahoo and DuckDuckGo. Last month, Microsoft integrated a cousin of ChatGPT, OpenAI’s AI-powered chat technology, into Bing. Rivals
Sanofi SA’s drug Dupixent succeeded in a late-stage trial for chronic obstructive pulmonary disease (COPD), raising the odds that the blockbuster would be the first biologic medicine cleared to treat the lung disorder. Dupixent, which is already prescribed for asthma and some skin conditions, showed a 30 percent reduction in the rate at which patients’ COPD worsened compared with those who received a placebo during the stage-three Boreas trial, the company said in a statement yesterday. The positive data could herald a new era of cutting-edge treatments for the life-threatening respiratory affliction and provide another major boost in demand for the French
RSS